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The  FDA  has responsibility  for ensuring  that prescription  drug  and  biological  products  including  vaccines
are  accompanied  by  labeling  that summarizes  scientiﬁc  information  concerning  their  safe  and  effective
use.  As part of  a  broader  effort  to improve  the content  and  format  of  prescription  drug  labeling FDA  pub-
lished  a ﬁnal  rule,  the  Content  and  Format  of Labeling  for  Human  Prescription  Drug  and  Biological  Products;
Requirements  for Pregnancy  and  Lactation  Labeling,  referred  to as the “Pregnancy  and  Lactation  Labeling
Rule  (PLLR).”  The  most  signiﬁcant  change  to be  implemented  by  this  Rule  is the  removal  of  the  letter
risk  categories  A, B, C, D  and  X from  all labeling,  replacing  them  with a narrative  summary  of  the  risks
of  using  a  drug  or biological  product  including  vaccines  during  pregnancy.  The PLLR  requires  an  evalua-
tion  of  available  information  about  a product’s  use  in pregnancy  and  provides  an  opportunity  to  update
labeling  when  new  information  about  use of  a  vaccine  in  pregnancy  becomes  available.  Implementation
of  the  provisions  articulated  in  the PLLR,  as  they apply  to vaccine  product  labeling,  will require  close
collaboration  between  FDA  and  the  vaccine  manufacturer  for both  currently  licensed  vaccines  and  those
in development.
© 2015  The  Author.  Published  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY  licenseThe FDA has responsibility for ensuring that prescription drug
nd biological products including vaccines are accompanied by
abeling that summarizes scientiﬁc information concerning their
afe and effective use [1]. Labeling, herein referred to as package
nsert or prescribing information, is the primary mechanism
hrough which FDA and drug manufacturers communicate essen-
ial, science-based information used by health care professionals in
aking prescribing decisions. Regulations contained in Title 21 of
he Code of Federal Regulations (CFR 201.56 and 201.57) describe
he content and format requirements for labeling information [2].
hey require that prescribing information must not be false or mis-
eading and must not contain implied claims or uses for which
here is inadequate evidence of safety or effectiveness. On January
4, 2006, FDA published a ﬁnal rule, referred to as the Physician
abeling Rule (PLR) that amended the requirements for the content
nd format of labeling for human prescription drug and biologi-
al products [3]. For prescription drug products subject to the PLR,
abeling must include three sections: (a) highlights of prescrib-
ng information (Highlights), containing information from the full
rescribing information (FPI) that health care practitioners most
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commonly reference and consider most important, (b) a table of
contents (Contents) listing the sections and subsections of the FPI
and (c) the full prescribing information (FPI) containing the detailed
prescribing information necessary for safe and effective use of the
product.
The “Indications and Usage” section of labeling which commu-
nicates a product’s approved indication(s) should clearly convey
the use(s) for which the product has been shown safe and effective,
accurately reﬂecting the scientiﬁc evidence. For biological prod-
ucts including vaccines, all indications listed in the “Indications and
Usage” section must be supported by substantial evidence of effec-
tiveness. Such evidence is expected to be derived from adequate
and well-controlled studies demonstrating the safety and effective-
ness of the vaccine for the intended indication and use. Of note, a
lack of substantial evidence of effectiveness and safety of the prod-
uct in pregnant women  does not necessarily preclude its use in
pregnancy. For a vaccine indicated for the prevention of a partic-
ular disease, use in pregnant women to prevent the target disease
in the vaccine recipient is permissible as long as the vaccine is not
contraindicated in pregnant women.For vaccines with labeling in PLR format, information relevant
to use during pregnancy is found in the section “Use in Speciﬁc
Populations.” This section of labeling summarizes important differ-
ences in response to the product and considerations for its use in
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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peciﬁc populations. As part of the January 2006 revisions to label-
ng requirements under the PLR, subsections on pregnancy, labor
nd delivery, and nursing mothers are included in the “Use in Spe-
iﬁc Populations” section.
FDA ﬁrst established labeling requirements and regulations to
ddress pregnancy, labor and delivery, and nursing mothers in 1979
CFR 201.57(f)(6) now located in CFR 201.80], following the West-
rn European thalidomide tragedy in 1962 [4]. The 1979 regulations
equired that the “Pregnancy” subsection contains information on
he drug’s teratogenic effects and other effects on reproduction
nd pregnancy and, when available, a description of human studies
ith the drug and data on its effects on later growth, development,
nd functional maturation of the child. The 1979 regulations also
equired that each product be classiﬁed under one of ﬁve preg-
ancy categories (A, B, C, D or X) on the basis of risk of reproductive
nd developmental adverse effects or, for certain categories, on the
asis of such risk weighed against potential beneﬁt.
As part of a broader effort to further improve the content and
ormat of prescription drug labeling, on December 3, 2014 FDA pub-
ished a ﬁnal rule, the Content and Format of Labeling for Human
rescription Drug and Biological Products; Requirements for Preg-
ancy and Lactation Labeling, referred to as the “Pregnancy and
actation Labeling Rule” (PLLR) [5]. The most signiﬁcant change to
e implemented by this Rule is the removal of the letter risk cat-
gories A, B, C, D and X from all labeling, replacing them with a
arrative summary of the risks of using a drug or biological prod-
ct during pregnancy. These summaries will be based on available
uman and or animal data and will be accompanied by a discus-
ion of the data. Additionally, the rule requires that prescription
rug labeling include relevant clinical information to help health
are providers make prescribing decisions and counsel women
bout the use of drugs during pregnancy and/or lactation. Infor-
ation for both pregnant and lactating women is presented in two
onsecutive label subsections of the “Use in Speciﬁc Populations”
ection, namely “Pregnancy” and “Lactation.” The “Lactation” sec-
ion replaces the “Nursing Mothers” subsection, and the “Labor and
elivery” subsection is now part of “Pregnancy.”
The Pregnancy subsection (8.1) includes information for a preg-
ancy exposure registry for the product when one is available. The
actation subsection (8.2) provides information about using the
rug while breastfeeding, such as the amount of drug in breast
ilk and potential effects on the breastfed infant. The three major
nformational components under the subsections Pregnancy and
actation include a risk summary, clinical considerations, and data
ection. Human data that may  be included in these subsections
f the labeling are those describing what is known about use of
he drug in pregnancy; these data may  be derived from clinical
rials, pregnancy exposure registries, other large scale epidemio-
ogic studies, or case series reporting a rare event. The Females and
ales of Reproductive Potential subsection (8.3) is new to the label-
ng and includes information, when necessary, about the need for
regnancy testing, contraception recommendations, and informa-
ion about infertility as it relates to the drug. The labeling changes
equired by the PLLR, effective June 30, 2015, are to provide more
eaningful information to help health care professionals to advise
omen about the use of drugs during pregnancy and lactation.
Under the previous regulations, prescribing information for US
icensed vaccines, with few exceptions, were classiﬁed either Cat-
gory B or Category C, allowing vaccination of pregnant women.
lthough the PLLR removes the pregnancy letter categories, it does
ot change the considerations for vaccination of pregnant women.
nstead, under the PLLR, narrative summaries of risks of a vac-
ine used during pregnancy and discussion of the supporting data
eplace the language that was required with each letter category,
[
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in an effort to provide more meaningful information for clinicians.
The provisions of the PLLR do not impact the requirement for sub-
stantial evidence of effectiveness and demonstration of safety in
order to support indications and usage speciﬁc to pregnancy such
as use of Tdap vaccines to prevent pertussis in neonates. Use of
vaccines in pregnant women is also guided by recommendations
from certain recommending bodies. For example, certain vaccines
are recommended for use during pregnancy such as inactivated
inﬂuenza vaccines because of concerns of increased morbidity due
to inﬂuenza [6,7]. The tetanus, diphtheria and acellular pertussis
(Tdap) vaccines have been recommended for pregnant women in
an effort to reduce the burden of pertussis in infants [8]. The new
requirements of the PLLR are not expected to impact existing rec-
ommendations on use of these vaccines in pregnancy.
To comply with the PLLR regulations, for all drugs and bio-
logical products, including vaccines, manufacturers are required
to evaluate existing labeling to ensure it accurately reﬂects cur-
rent knowledge about use of the product during pregnancy and to
update labeling when new information becomes available. Of note,
there is no requirement for the manufacturer to conduct additional
studies. In general, data from use of vaccines during pregnancy
are derived from post-marketing studies and/or from maternal
immunization studies published in the literature. Thus, informa-
tion to be included in the Pregnancy and Lactation subsection
could come from various sources such as well conducted clinical
trials, pregnancy exposure registries, observational post-licensure
studies, and animal studies. Manufacturers will be required to
include clinically relevant information from such published studies
in the labeling. Of note, to be included in the prescribing infor-
mation data must be derived from studies conducted with the
speciﬁc product unless there is evidence of risk apparent from
data accrued using a closely related product or products. The
agency has published guidance for industry to assist applicants in
complying with the new content and format requirements of the
PLLR [9].
In summary, the PLLR requires an evaluation of available infor-
mation about a product’s use in pregnancy and provides an
opportunity to update labeling when new information about use
of the vaccine in pregnancy becomes available. This information
will provide the HCP with meaningful data to make prescribing
decisions and to counsel women. It does not impact vaccination
of pregnant women with currently licensed vaccines, the require-
ments for safety data and substantial evidence of effectiveness
to support vaccine indications, or the recommendations made by
health policy makers regarding use of certain vaccines in preg-
nancy. Implementation of the provisions articulated in the PLLR,
as they apply to vaccine product labeling, will require close col-
laboration between FDA and the vaccine manufacturer for both
currently licensed vaccines and those in development and will be
in accordance with published guidance.
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